Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab plus chemotherapy for advanced esophageal squamous cell carcinoma
ChiCTR2300072992Phase 2Not yet recruiting
- Sponsor
- National Cancer Center/Chinese Academy of Medical Sciences
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of serplulimab in Esophageal Squamous Cell Carcinoma (ESCC) (2 cohorts), sponsored by National Cancer Center/Chinese Academy of Medical Sciences. Primary endpoint: Clinical complete response rate. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
serplulimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2300072992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072992.